Harry Paul Erba, MD Professor of Medicine and Member of the Duke Cancer Institute
Harry Erba, MD, a respected Duke University Medicine Professor, refines intensive chemotherapy for FLT3 mutated AML patients. He validates Midostaurin’s potential via the RATIFY trial and now focuses on potent second-gen FLT3 inhibitors. In the quantum first study, quizartinib enhances ITD mutated AML survival, particularly in younger patients (hazard ratio 0.68). Older patients also benefit, though less significantly (hazard ratio 0.9).
REGISTER NOW TO JOIN US AT THESE UPCOMING EVENTS
AML-ALL US – Online content available – https://aml-allus2023.md-education.com/register/
AML-ALL EU – Registration open – https://aml-alleu2023.md-education.com/register/
MPN-MDS EU – registration open – https://mpn-mdseu2023.md-education.com/register/
Harry Erba highlights second-gen FLT3 inhibitors’ potential toxicity, especially myelosuppression, affecting older patients more. Deeper data analysis is underway.
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content